Ratings by Leerink Partners (Marc H. Goodman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/31/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Aptinyx | APTX | Downgrade | Market Perform (Outperform) |
0.59 (0.06) |
-89.83% | Details | |
| 10/12/2021 | Adamas Pharmaceuticals | ADMS | Downgrade | Market Perform (Outperform) |
4.61 (8.22) |
78.31% | Details | |
| 6/10/2021 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2020 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2020 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/20/2020 | Aptinyx | APTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2020 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2019 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details |
